|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091196 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-23 08:58:12 |
|
注册时间: Date of Registration: |
2024-10-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国急性缺血性卒中替奈普酶溶栓治疗队列 |
|
Public title: |
Chinese Cohort of Tenecteplase Thrombolysis for Acute Ischemic Stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国急性缺血性卒中替奈普酶溶栓治疗队列(CREAT-TNK研究) |
|
Scientific title: |
Chinese Cohort of Tenecteplase Thrombolysis for Acute Ischemic Stroke((CREAT-TNK Study) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨杰 |
研究负责人: |
资文杰 |
|
Applicant: |
Jie Yang |
Study leader: |
Wenjie Zi |
|
申请注册联系人电话: Applicant telephone: |
+86 137 5293 2078 |
研究负责人电话:
Study leader's |
+86 182 0519 2720 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yangjie_0929@126.com |
研究负责人电子邮件: Study leader's E-mail: |
Ziwenjie1981@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥正街183号新桥医院神经内科 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街183号新桥医院神经内科 |
|
Applicant address: |
Department of Neurology, Xinqiao Hospital, 183 Xinqiao Main Street, Shapingba District, |
Study leader's address: |
Department of Neurology, Xinqiao Hospital, 183 Xinqiao Main Street, Shapingba District, |
|
申请注册联系人邮政编码: Applicant postcode: |
400037 |
研究负责人邮政编码: Study leader's postcode: |
400037 |
|
申请人所在单位: |
中国人民解放军陆军军医大学第二附属医院 |
||
|
Applicant's institution: |
Second Affiliated Hospital of Army Medical University, PLA |
||
|
研究负责人所在单位: |
中国人民解放军陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
Second Affiliated Hospital of Army Medical University, PLA |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-研第238-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Second Affiliated Hospital of Army Medical University, People's Liberation Army of China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-08 00:00:00 | ||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Lanlan Hu |
||
|
伦理委员会联系地址: |
陆军军医大学第二附属医院办公楼二楼医学伦理委员会办公室 |
||
|
Contact Address of the ethic committee: |
Office of the Medical Ethics Committee, Second Floor, Administrative Building, The Second Affiliated Hospital of Army Medical University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6877 5422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Second Affiliated Hospital of Army Medical University, PLA |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街183号新桥医院神经内科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Department of Neurology, Xinqiao Hospital, 183 Xinqiao Main Street, Shapingba District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
急性大面积脑梗死血管内治疗策略优化的研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
Optimization of endovascular treatment strategy for acute massive cerebral infarction |
||||||||||||||||||||||
|
研究疾病: |
缺血性卒中 |
||||||||||||||||||||||
|
Target disease: |
Lschemic stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探讨急性缺血性卒中患者接受rhTNK-tPA溶栓的安全性和有效性的临床结局 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the safety and efficacy of rhTNK-tPA thrombolytic therapy in patients with acute ischemic stroke |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1) 年龄≥18 周岁; 2) 根据临床症状及体征初步判断为急性缺血性脑卒中; 3) 影像学CT/MRI确认为急性缺血性脑卒中; 4) 使用替奈普酶溶栓; 5) 患者或家属签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Age ≥18 years; 2) Preliminary diagnosis of acute ischemic stroke according to clinical symptoms and signs; 3) Acute ischemic stroke confirmed by CT/MRI; 4) Thrombolysis with tenecteplase; 5) Patients or their family members provided written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1) 经头颅CT或MRI证实颅内出血; 2) 预期不能完成随访; 3) 研究者认为不适合参与研究的患者被排除在外; 4) 活动性内出血; 5) 目前或过去6个月中有明显的出血性疾病; 6) 已知有颅内出血史或疑有颅内出血; 7) 已知出血体质; 8) 显著的或是近期有严重的或危险的出血; 9) 中枢神经系统病变或创伤史(如,颅内肿瘤,动静脉畸形或动脉瘤,颅内、椎管内手术); 10) 动脉瘤性蛛网膜下腔出血或疑有蛛网膜下腔出血; 11) 有出血倾向的肿瘤; 12) 细菌性心内膜炎或心包炎; 13) 最近(2周内)曾进行较长时间(>2分钟)的心肺复苏,分娩或非压力性血管穿刺(如锁骨下或颈静脉穿刺); 14) 急性胰腺炎、活动性消化道溃疡、动脉瘤或动脉 / 静脉畸形; 15) 口服抗凝剂治疗且 INR>1.3; 16) 严重的肝病,包括肝功能衰竭、肝硬变、门静脉高压(食管静脉曲张)及活动性肝炎; 17) 过去3个月内有严重的创伤或大手术。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Intracranial hemorrhage confirmed by head CT or MRI; 2) Expected inability to complete follow-up; 3) Patients who were deemed unsuitable for study participation by the investigator; 4) Active internal bleeding; 5) Significant bleeding illness currently or in the past 6 months; 6) Known or suspected history of intracranial hemorrhage; 7) Known bleeding constitution; 8) Significant or recent severe or dangerous bleeding; 9) A history of central nervous system disease or trauma (e.g., intracranial tumor, arteriovenous malformation or aneurysm, intracranial or intraspinal surgery); 10) Aneurysmal subarachnoid hemorrhage or suspected subarachnoid hemorrhage; 11) Tumors with a tendency to bleed; 12) Bacterial endocarditis or pericarditis; 13) A recent (within 2 weeks) prolonged (>2 minutes) cardiopulmonary resuscitation, delivery, or nonpressure vessel puncture (e.g., subclavian or jugular venepuncture); 14) Acute pancreatitis, active gastrointestinal ulcer, aneurysm or arterial/venous malformation; 15) Oral anticoagulant therapy and INR>1.3; 16) Severe liver disease, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis; 17) Severe trauma or major surgery in the past 3 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-20 00:00:00至 To 2033-05-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-01 00:00:00 至 To 2032-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
相关论文发表5年后在Resman平台公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Related papers published five years later, the IPD will be shared on ResMan. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例报告表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |